Porokeratosis

Meet the patient

A 48-year-old woman arrives in summer with dozens of small, itchless, ring-shaped plaques over her forearms and shins — each with a tiny raised edge she can catch with her fingernail, and a pale, slightly thinned centre. They multiplied over the last two summers and never quite go. Run a finger across one and you feel a definite ridge; the centre is flat and atrophic. Before reaching for an antifungal, hold the one structure that ties every variant together — and the one biopsy site that finds it.[1]

One clone, one lamella, one ridge you can feel

Porokeratosis is a clonal expansion of an abnormal keratinocyte that grows outwards and lays down a ring of disordered cornification at its leading edge. The clinical ridge you feel is the histological cornoid lamella — the same structure, felt and seen.[1][2]

Etymology worth a viva mark: Mibelli named it porokeratosis in 1893 from the Greek poros, a pore, because he blamed the eccrine sweat-pore. He was wrong — it is a clonal keratinocyte disorder — but the name stuck, and the true mechanism took a century to arrive.[1]

The hallmark is the cornoid lamella: a discrete vertical column of parakeratotic, nucleated cells in the stratum corneum, tilting away from the centre, sitting over a focal zone where the granular layer is absent, with dyskeratotic keratinocytes immediately beneath.[1]

[1]

The classic trap: the cornoid lamella is a focal finding at the active edge. A punch biopsy through the flat central atrophy returns non-specific and misses the diagnosis every time. Biopsy through the raised ridge — or use dermoscopy to pick its most keratotic segment.[3]

The five faces — same lamella, five patterns

All five variants share the cornoid lamella; they differ only in size, number, distribution and age of onset — and the variant decides the cancer risk.[1][6]

[1]

DSAP is the one you will meet most often — multiple small annular plaques on the forearms, shins and V of the neck of adults, worsening each summer, sparing the palms and soles.[6]

Linear porokeratosis is the one you must not miss — streaks along Blaschko's lines from somatic mosaicism, and the highest malignant transformation rate of all. Any new nodule, ulcer or pain within a linear lesion is cancer until proved otherwise.[11]

The genes — and the rational fix

Familial DSAP is autosomal dominant, and the culprit genes sit in the mevalonate–cholesterol pathway — which is exactly why a statin-plus-cholesterol cream works.[7]

Two genes account for most familial cases: MVK (mevalonate kinase, also mutated in mevalonate kinase deficiency) and SLC17A9; sporadic and linear cases are mostly somatic mosaics.[8][9]

The mechanism is elegant: loss of MVK function starves the keratinocyte of downstream cholesterol and isoprenoids, so differentiation fails and the cornoid lamella forms.[7]

That makes the treatment pathogenesis-directed. Topical lovastatin, an HMG-CoA reductase inhibitor, plus cholesterol — which bypasses the MVK block — outperformed lovastatin alone in the 2023 JAMA Dermatology randomised trial of Liu and colleagues.[4][3]

Triggers, and the paraneoplastic flag

Ultraviolet light is the dominant trigger for DSAP; immunosuppression amplifies every variant — and a sudden eruptive shower in the wrong patient is a cancer warning, not a skin disease.[6]

Recognised precipitants include UV (especially DSAP), solid-organ transplantation, HIV, chronic lymphocytic leukaemia, prior radiotherapy, PUVA, and certain drugs such as thiazides and anti-tuberculous agents. In a transplant recipient, a florid DSAP-like eruption can be the first clue to over-immunosuppression.[3]

The classic trap: abrupt-onset eruptive DSAP in an adult without a UV or immunosuppression trigger is a recognised paraneoplastic dermatosis — screen for haematological, hepatic and gastrointestinal malignancy. Treating the tumour can make the skin regress.[11]

Meet it at the bedside — and under the dermatoscope

Slide a finger across the lesion: the ridge you feel is the cornoid lamella. Then confirm with dermoscopy before you biopsy.[1]

Dermoscopy shows a central structureless white-to-yellow or pink area ringed by a keratotic peripheral ridge studded with red, brown or black speckles — the dilated capillaries and haemorrhage within the lamella. That peripheral-keratotic-ridge-with-central-structureless-area pattern is diagnostic in experienced hands and catches lesions before the ridge is palpable.[13][12]

The ridge sign cleanly separates porokeratosis from its mimics, and so does a punch taken through the ridge rather than the centre.[13]

The face-off — annular plaque with a raised border

An annular plaque with a palpable ridge and central atrophy is porokeratosis until a biopsy or a KOH preparation says otherwise.[10]

[8]

The classic trap: a chronic genitogluteal or perianal plaque labelled intertrigo or candida that never clears is porokeratosis ptychotropica — biopsy it, because this variant carries a real malignant risk and is misdiagnosed for years.[12][5]

The danger — malignant transformation

Every long-standing lesion can turn into squamous cell carcinoma, and the linear and giant variants do it most often — so biopsy any change, every time.[10][11]

Pooled series put the overall transformation rate around 5 to 15 percent; the linear and giant forms climb to 7 to 11 percent, as does disease in organ-transplant recipients. The same clone that built the cornoid lamella is the clone that becomes SCC.[11]

The treatment ladder — and the one rational fix

Photoprotect first; reach for pathogenesis-directed lovastatin plus cholesterol next; reserve destruction and retinoids for resistant or extensive disease.[2][3]

[3]

The ladder runs conservative to aggressive:[2]

[2]

Ablative fractional CO2 laser, often paired with an antioxidant serum to blunt post-inflammatory pigment, has published evidence for clearance in extensive DSAP and PPPD.[14]

[4] [2]

[3]

The mantra: feel the ridge, biopsy the ridge, treat the clone with lovastatin plus cholesterol — and watch the linear ones turn.[1]

Porokeratosis is chronic and persistent; spontaneous remission is uncommon outside the paraneoplastic form, where treating the tumour can clear the skin. Complete excision cures an individual plaque, but the long game is photoprotection and surveillance.[10]

Ward-round test

A 48-year-old woman has 50 annular 6 mm plaques with raised borders on her forearms and shins, worsening each summer. Diagnosis, genetic basis, and first-line pathogenesis-directed treatment?

Disseminated superficial actinic porokeratosis (DSAP) — the commonest variant. Autosomal dominant, with MVK and SLC17A9 mutations in the mevalonate–cholesterol pathway. First-line pathogenesis-directed treatment is topical 2% lovastatin plus 2% cholesterol cream twice daily for 12 weeks, with strict photoprotection.[4]

Which variant carries the highest risk of malignant transformation, and how do you manage it?

Linear porokeratosis (and the giant form) — transformation up to 7–11% in some series. Manage with 3- to 6-monthly dermatology review for the first five years then annually, biopsy any change, and combine pathogenesis-directed topical therapy with oral retinoids or procedural ablation of thickened plaques.[11]

Where do you biopsy a suspected porokeratosis, and why?

Through the raised peripheral ridge — the cornoid lamella is a focal finding at the active edge. A central punch misses it every time and returns non-specific.[3]

A 62-year-old man develops eruptive, intensely itchy porokeratotic papules over six weeks, with no UV trigger and no immunosuppression. Next step?

A paraneoplastic screen — full blood count and peripheral smear, ESR and CRP, LFTs, LDH, faecal immunochemical test, age-appropriate cancer imaging (CT chest, abdomen and pelvis), and HIV serology. Treat the underlying tumour; the skin may regress.[11]

A chronic, well-demarcated keratotic plaque in the gluteal cleft has been treated as candida for two years. What must you do?

Biopsy through the ridge to exclude porokeratosis ptychotropica (or Bowen's disease). Ptychotropica mimics intertrigo and inverse psoriasis, is misdiagnosed for years, and carries a real malignant-transformation risk.[12]

References

1. [1]Velasco-Tamariz V, et al. Porokeratosis: A Review of Its Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment. Actas dermo-sifiliograficas, 2020.PMID 32401728
2. [2]Pini A, et al. Treatment of Porokeratosis: A Systematic Review. American journal of clinical dermatology, 2017.PMID 28283894
3. [3]Nehal KS, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. JAAD case reports, 2020.PMID 31449901
4. [4]Liu J, et al. Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for Porokeratosis. JAMA dermatology, 2023.PMID 36947042
5. [5]Yorulmaz A, et al. Genitogluteal porokeratosis: a clinical review. International journal of dermatology, 2018.PMID 29750048
6. [6]Sertznig P, et al. Disseminated Superficial Actinic Porokeratosis. New England Journal of Medicine, 2026.PMID 29083728
7. [7]Zhang Z, et al. Genomic variations of the mevalonate pathway in porokeratosis. eLife, 2015.PMID 26202976
8. [8]Zhou Y, et al. Identification of three mutations in the MVK gene in six patients associated with disseminated superficial actinic porokeratosis. Journal of dermatological science, 2016.PMID 26794421
9. [9]Lu WS, et al. A novel non-frameshift deletion in MVK gene responsible for disseminated superficial actinic porokeratosis in one Chinese family. Journal of the European Academy of Dermatology and Venereology, 2017.PMID 28543715
10. [10]Yang W, et al. A case of squamous cell carcinoma arising in a giant porokeratosis previously diagnosed as psoriasis. Clinical, cosmetic and investigational dermatology, 2023.PMID 37397406
11. [11]Huang X, et al. The Malignancy Potential of Porokeratosis: A Single-Center Retrospective Study. Clinical, cosmetic and investigational dermatology, 2021.PMID 33680623
12. [12]Cataldi G, et al. Porokeratosis Ptychotropica: Dermoscopy, Reflectance Confocal Microscopy, and Histopathological Correlation. Dermatology practical & conceptual, 2021.PMID 35068510
13. [13]Pizzigoni S, et al. Porokeratosis simulating Bowen's disease on dermoscopy. Giornale italiano di dermatologia e venereologia, 2016.PMID 28300916
14. [14]Kubiak M, et al. Successful Treatment of Porokeratosis With Ablative Fractional Carbon Dioxide Laser and Vitamin C, E, and Ferulic Acid Serum. Dermatologic surgery, 2019.PMID 31741362